Activated natural killer cells - NantKwest

Drug Profile

Activated natural killer cells - NantKwest

Alternative Names: aNK cells - NantKwest; CST-101; Neukoplast; NK-92 cells; ZRx-101

Latest Information Update: 21 Jun 2017

Price : $50

At a glance

  • Originator ZelleRx
  • Developer Johann Wolfgang Goethe-Universitat Frankfurt am Main; NantKwest; Rush University; University of Pittsburgh Medical Center; ZelleRx
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Natural killer cell receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Merkel cell carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Merkel cell carcinoma
  • Phase I Acute myeloid leukaemia
  • Preclinical Hepatocellular carcinoma; Infections
  • No development reported Malignant melanoma; Renal cancer; Solid tumours
  • Discontinued Graft-versus-host disease; Leukaemia; Multiple myeloma; Sarcoma

Most Recent Events

  • 06 Jun 2017 NantKwest plans to expand the NANT Cancer Vaccine Program and initiate multiple clinical trials in Lung cancer, Breast cancer, Colon cancer, Head and neck cancer, Melanoma, Ovarian cancer, Urothelial cancer, Hodgkins and non-Hodgkins lymphoma, Sarcoma, and Merkel cell carcinoma
  • 09 May 2017 The US FDA authorises an Investigational New Drug Application for NANT Cancer Vaccine for a phase Ib/II trial enrolment for Pancreatic cancer
  • 19 Apr 2017 NantCell plans the phase Ib/II QUILT-3.039 trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater) (NCT03136406)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top